


## AEEA-AEEA

Cat. No.:	HY-W125504
CAS No.:	1143516-05-5
Molecular Formula:	C <sub>12</sub> H <sub>24</sub> N <sub>2</sub> O <sub>7</sub>
Molecular Weight:	308.33
Target:	ADC Linker; PROTAC Linkers
Pathway:	Antibody-drug Conjugate/ADC Related; PROTAC
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



## BIOLOGICAL ACTIVITY

Description	AEEA-AEEA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). AEEA-AEEA is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
IC <sub>50</sub> & Target	Cleavable Linker
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[1]</sup> . PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

- [1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov.* 2017;16(5):315-337.
- [2]. Nalawansa DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol.* 2020;27(8):998-985.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA